Ann: Positive 28-day Clinical Trial Data in Cohort B, page-23

I tend to disagree re insiders, price was higher only two weeks ago. No major on market volume going through since then.
My guess is Ross is more scientist than stock promoter. Trading is still mainly retail and those investor avenues are probably not being pushed. At around $100k a day volume, it's still too illiquid for most institutions to want to buy on market. Fidelity bought half their holding on market and saw price more than double over their buying period.

Congrats to Ross and Cynata on a fantastic result. Great result for investors and an even better result for those (and future) GVHD sufferers. This stock is much more attractive than it was yesterday. Would expect very positive updates come out of Shaw and Wainwright.